VAC approval is nice, but how many sales are likely to smaller hospitals with limited staff capacity? Many of these smaller hospitals are likely waiting on Recell Go. Without Go, sales will be much more slow. The August VAC success projection for 2024 predated the FDA delay. Training for each ease of use sale will take up considerable time and expense once Avita tries to spread its wings to said smaller hospitals. Also, Go needed for international expansion and vitiligo. It’s a crapshoot.
VAC approval is nice, but how many sales are likely to smaller...
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.62 |
Change
-0.150(5.42%) |
Mkt cap ! $157.7M | |||
| Open | High | Low | Value | Volume |
| $2.62 | $2.66 | $2.58 | $1.612M | 614.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 13249 | $2.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.66 | 3448 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.62 |
Change
-0.150 ( 6.19 %) |
||||
| Open | High | Low | Volume | ||
| $2.61 | $2.65 | $2.61 | 10832 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| AVH (ASX) Chart |